Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof

A crystal form of a pharmaceutically acceptable salt of a compound of formula I, wherein the crystal form of the pharmaceutically acceptable salt of the compound of formula I is a crystal form A of a hydrochloride salt of the compound of formula I, a crystal form A of a citrate salt of the compound of formula I, a crystal form A of a maleate salt of the compound of formula I, a crystal form A of a fumarate salt of the compound of formula I, a crystal form A of a methanesulfonate salt of the compound of formula I, a crystal form B of a methanesulfonate salt of the compound of formula I, a crystal form C of a methanesulfonate salt of the compound of formula I, a crystal form A of a p-toluenesulfonate salt of the compound of formula I, a crystal form A of a cyclamate salt of the compound of formula I, a crystal form A of a sulfate salt of the compound of formula I, a crystal form D of a sulfate salt of the compound of formula I, a crystal form B of a sulfate salt of the compound of formula I, a crystal form C of a sulfate salt of the compound of formula I, a crystal form E of a sulfate salt of the compound of formula I, or a crystal form F of a sulfate of the compound of formula I;

• the crystal form A of the hydrochloride salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 8.83±0.2°, 13.24±0.2°, 24.25±0.2°, and 18.31±0.2°;
• the crystal form A of the citrate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 17.87±0.2°, 14.97±0.2°, 17.45±0.2°, and 17.01±0.2°;
• the crystal form A of the maleate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 16.47±0.2°, 4.58±0.2°, 10.97±0.2°, and 22.91±0.2°;
• the crystal form A of the fumarate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 28.83±0.2°, 5.03±0.2°, 16.15±0.2°, and 13.11±0.2°;
• the crystal form A of the methanesulfonate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 5.76±0.2°, 14.75±0.2°, 5.11±0.2°, and 17.54±0.2°;
• the crystal form B of the methanesulfonate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 18.83±0.2°, 16.51±0.2°, 25.51±0.2°, and 10.98±0.2°;
• the crystal form C of the methanesulfonate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 19.57±0.2°, 19.98±0.2°, 16.50±0.2°, and 18.20±0.2°;
• the crystal form A of the p-toluenesulfonate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 5.80±0.2°, 19.70±0.2°, 22.36±0.2°, and 11.57±0.2°;
• the crystal form A of the cyclamate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 6.41±0.2°, 16.47±0.2°, 18.57±0.2°, and 10.95±0.2°;
• the crystal form A of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 14.60±0.2°, 11.67±0.2°, 21.09±0.2°, and 13.32±0.2°;
• the crystal form D of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 14.60±0.2°, 25.31±0.2°, 19.85±0.2°, and 20.07±0.2°;
• the crystal form I of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 12.92±0.2°, 26.90±0.2°, 15.86±0.2°, and 23.02±0.2°;
• the crystal form B of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 25.15±0.2°, 18.71±0.2°, 3.13±0.2°, and 23.28±0.2°;
• the crystal form C of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 5.55±0.2°, 14.72±0.2°, 16.75±0.2°, and 27.35±0.2°;
• the crystal form E of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 16.39±0.2°, 12.75±0.2°, 14.32±0.2°, and 20.28±0.2°;
• the crystal form F of the sulfate salt of the compound of formula I has an X-ray powder diffraction pattern expressed at a 2θ angle comprising diffraction peaks at the following 2θ angles:
• 24.91±0.2°, 20.60±0.2°, 27.62±0.2°, and 16.04±0.2°.